Effective inhibition of foot-and-mouth disease virus (FMDV) replication in vitro by vector-delivered microRNAs targeting the 3D gene
Virology Journalvolume 8, Article number: 292 (2011)
Foot-and-mouth disease virus (FMDV) causes an economically important and highly contagious disease of cloven-hoofed animals. RNAi triggered by small RNA molecules, including siRNAs and miRNAs, offers a new approach for controlling viral infections. There is no report available for FMDV inhibition by vector-delivered miRNA, although miRNA is believed to have more potential than siRNA. In this study, the inhibitory effects of vector-delivered miRNAs targeting the 3D gene on FMDV replication were examined.
Four pairs of oligonucleotides encoding 3D-specific miRNA of FMDV were designed and selected for construction of miRNA expression plasmids. In the reporter assays, two of four miRNA expression plasmids were able to significantly silence the expression of 3D-GFP fusion proteins from the reporter plasmid, p3D-GFP, which was cotransfected with each miRNA expression plasmid. After detecting the silencing effects of the reporter genes, the inhibitory effects of FMDV replication were determined in the miRNA expression plasmid-transfected and FMDV-infected cells. Virus titration and real-time RT-PCR assays showed that the p3D715-miR and p3D983-miR plasmids were able to potently inhibit the replication of FMDV when BHK-21 cells were infected with FMDV.
Our results indicated that vector-delivered miRNAs targeting the 3D gene efficiently inhibits FMDV replication in vitro. This finding provides evidence that miRNAs could be used as a potential tool against FMDV infection.
Foot-and-mouth disease (FMD) is an economically important and highly contagious disease of cloven-hoofed animals, most notably of cattle, pigs and sheep, as well as several wild-life species [1, 2]. The ability of FMD virus (FMDV) to spread rapidly in susceptible animals makes FMD a disease that is serious enough to be monitored by the World Organization for Animal Health (OIE). FMDV is the prototype member of the Aphthovirus genus of the family Picornaviridae. The virus is antigenically highly variable and consists of seven serotypes (A, O, C, Asia1, SAT1, SAT2, and SAT3) and multiple subtypes . FMDV contains a positive-sense, single-stranded RNA genome of 8,500 nucleotides (nt) with a 50 nt terminus covalently bound to a small viral polypeptide VPg (3B), and a 30 nt poly(A) tail . The genome contains a long open reading frame (ORF) translated into a single polypeptide that can be cleaved into four structural proteins (VP4, VP2, VP3, and VP1), and 10 non-structural proteins (L, 2A, 2B, 2C, 3A, 3B1, 3B2, 3B3, 3C, and 3D) [3, 5]. Of particular importance to viral replication is the 3D gene encoding the RNA-dependent RNA polymerase (RDRP). In a mechanism catalyzed by two bivalent metal ions, the 3D enzyme elongates a primer to copy the viral RNA template (plus strand). The newly synthesized minus strand folds back on itself to generate a template-primer structure, which is elongated by the 3D gene product to form covalently linked dimeric RNA molecules [6, 7]. Due to its significance in viral replication, the 3D gene was employed as an RNAi target in this study.
RNA interference (RNAi) is an evolutionarily conserved mechanism of sequence-specific post-transcriptional gene silencing triggered by double-stranded RNA (dsRNA). In the process, the cellular complex Dicer cleaves a dsRNA molecule to generate discrete 21-23 nt small interfering RNAs (siRNAs) or microRNAs (miRNAs), which guide the RNAi-induced silencing complex (RISC) to cleave the target mRNAs [8–10]. Because of the high rapidity and specificity of the RNAi effect, this method may complement and improve the traditional tools available to control important animal pathogens. In the past, siRNAs have been widely studied for their effects on FMDV [11–16]. Recently, artificial miRNA has been developed [17, 18]. It has been demonstrated that expression of miRNA vectors is more effective and less toxic than regular siRNA vectors [19–21]. In order to explore a new approach to inhibit FMDV, here we report on vector-delivered miRNA molecules that were studied for their inhibitory effects on FMDV replication. Our results show for the first time that vector-delivered miRNAs are able to efficiently inhibit FMDV replication. This study provides not only an experimental basis for the development of a new anti-FMDV strategy, but also for a new approach to study FMDV infection and replication.
Cell culture and viruses
Baby hamster kidney (BHK-21) cells were grown in Dulbecco's Modified Eagle's Medium (DMEM, GIBCO, Invitrogen Corporation, USA) supplemented with 10% heat-inactivated fetal bovine serum (FBS). The cultures were maintained at 37 °C in a 5% CO2 humidified incubator. FMDV isolates of strain O/CHA/99 (GenBank accession number AF506822)  were used for viral challenge. FMDV titers were determined in BHK-21 cells, and 50% tissue culture infective dose (TCID50) was calculated using the Reed-Muench method .
Selection of target sequences
The 3D gene is highly conserved among different FMDV serotypes and consists of 1410 nucleotides and encoding a 470-amino-acid protein with a molecular mass of 55 kDa . The reference sequences of the 3D regions of the FMDV genome were obtained from the National Center for Biotechnology Information (NCBI) and compared with that of O/CHA/99 by the Laser-gene analysis software package (DNASTAR, USA). Four pairs of oligonucleotides (3D657, 3D715, 3D983 and 3D1311) encoding 3D-specific miRNA of FMDV were designed using the miRNA design algorithm (http://rnaidesigner.invitrogen.com/rnaiexpress/, Table 1). Sequence alignment showed that all four were located in the conserved regions of the 3D gene of different FMDV isolates and thus were selected for corresponding pre-miRNA oligonucleotide synthesis (Figure 1A).
Construction of miRNA expression plasmids
Complementary single-stranded DNA oligos (top and bottom strands) encoding four pre-miRNAs were synthesized, annealed, and ligated into pcDNA6.2-GW-miR vectors (Invitrogen, USA), a Pol II miR RNAi expression vector containing specific miR-155 flanking sequences (Figure 1B). The ligation mixture was then transformed into competent E. coli DH5α cells following the manufacturer's protocol. Plasmid DNAs were isolated and purified with Plasmid Miniprep Kit (TaKaRa, Japan). The pcDNA6.2-GW-miR-negative control plasmid contains an insert that can form a hairpin structure, which is processed into mature miRNA, but is predicted not to target any known vertebrate gene. Their corresponding sequences are separately shown in Table 1. The sequences of the inserts were checked by DNA sequencing (TaKaRa, Japan).
Construction of reporter plasmid
To provide a reporting system for detecting miRNA function, the recombinant plasmid p3D-GFP, containing the whole length of 3D gene, was constructed as follows: BHK-21 cells infected with FMDV (O/CHA/99) were lysed by repeated freeze-thaw cycles. Cell debris was removed by centrifugation for 10 min at 4000 rpm. The RNA was extracted from 350 μL of the clarified infected cell culture supernatant using Mini RNeasy Kit (Qiagen, Germany) as per recommendation of the manufacturer. Reverse transcription (RT) was carried out using Avian Myeloblastosis Virus (AMV) reverse transcriptase (TaKaRa, Japan) and an antisense Xba I-adapter primer, 3DR. The reaction mixture was incubated at 42°C for 1 h. Additional incubation at 95°C for 5 min inactivated the enzyme. The PCR amplification of 3D cDNA fragments was carried out using the primer 3DR and a sense Kpn I-adapter primer, 3DF. The PCR products were then cloned into the unique site of Kpn I and Xba I of the pcDNA3.1-CT-GFP vector (Invitrogen, USA). Competent Escherichia coli TOP 10 cells were transformed with the vector by heat shock. The sequences of the inserts were checked by restriction enzyme digestion and DNA sequencing (TaKaRa, Japan). To monitor fusion protein expression as an indicator of interference by miRNAs candidates, the constructed plasmid p3D-GFP was only transfected into BHK-21 cells using Lipofectamine 2000 (Invitrogen, USA) per the manufacturer's protocol, and the transfected cells were then examined by fluorescence microscopy.
Silencing effect of miRNAs on reporter gene expression
Vector-delivered miRNAs were initially tested for sequence-specificity for the target 3D gene by employing a transient transfection of a reporter plasmid p3D-GFP expressing 3D. BHK-21 cells were seeded into 24-well cell culture plates without antibiotics for about 24 h before transfection at a cell confluence of approximately 80-90% and co-transfected in triplicate with Lipofectamine 2000 and Opti-MEM I Reduced Serum Medium (Invitrogen, USA) in the presence of 0.2 μg of reporter plasmid p3D-GFP and 0.5 μg of each miRNA expression plasmid. At 24 and 48 h after transfection, cells were examined under a fluorescence microscope and photographed using a video camera.
Inhibitory effect of miRNAs on FMDV replication
To detect the inhibitory effect of vector-delivered miRNAs on FMDV replication, BHK-21 cells were cultured in 24-well cell culture plates and transfected with miRNA-expressing plasmids in triplicate. After incubation for an additional 24 h, the transfection complex was removed and cells were washed twice with DMEM. A viral suspension titrated at 10-6.0 TCID50 per 0.1 ml was used for viral challenge. The transfected cells in one well of the 24-well plates were then infected with 500 μl of 100 TCID50 of FMDV. After 1 h of absorption, the inoculum was removed and the cells were washed twice with DMEM. The infection then proceeded in DMEM without FBS. At 24 h and 48 h after infection, cell cultures were harvested by three freeze-thaw cycles and stored at -80°C, until virus titer values were measured according to the TCID50 method.
To quantitatively detect the gene silencing effects of the vector-delivered miRNAs, total RNA was extracted from plasmid-transfected and virus-infected BHK-21 cell cultures with Mini RNeasy Kit (Qiagen, Germany) and subjected to real-time RT-PCR analysis. Real-time RT-PCR data were analyzed using the comparative CT method (ΔΔCT) [24, 25]. Hamster GAPDH from BHK-21 cells was chosen as a reference gene for internal control. Differences between the CT values of the target gene (3D) and the internal control (ΔCT = CTtarget--CTinternal control) were calculated to normalize the differences in the amount of total cDNA added to each reaction and the efficiency of the real-time RT-PCR. The negative control (pNC-miR) was used as a reference for each comparison. Differences between the ΔCT of each 3D-specfic miRNA expression plasmid and reference sample (ΔΔCT = (CTtarget--CTinternal control) 3D-specfic miRNA plasmid--(CTtarget--CTinternal control)pNC-miR) were calculated. Real-time PCR was performed with a Mx3000P real-time PCR system (Stratagene, USA) using a SYBR® Premix Ex Taq™ kit (TaKaRa, Japan) as follows: After treatment with RNase-free DNase I, 2 μg of each total RNA sample was reverse-transcribed with PrimerScript RT Enzyme Mix I, Oligo dT18 primer and random primers. The real-time PCR was carried out in triplicate in a total volume of 50 μl containing 25 μl of SYBR premix Ex Taq™, 1.0 μl of ROX Reference Dye, 10 pmol each of the Forward and Reverse Primers (Table 2) and 4 μl of the cDNA sample. Cycling conditions for the real-time PCR were: 10 sec at 95°C for predenaturation, 40 cycles of 5 sec at 95°C and 34 sec at 60°C, followed by 1 cycle of 15 sec at 95°C, 1 h at 60°C and 15 sec at 95°C for the dissociation stage. The fluorescence output for each cycle was measured upon the completion of the entire run. The expression level of the target gene could be calculated by 2--ΔΔCT and the value stood for an n-fold difference relative to the negative sample. To confirm the specific amplification, melt-curve analysis of the RT-PCR products was performed according to the manufacturer's protocol (Stratagene, USA).
Identification of miRNA-expression plasmids and reporter plasmid
The pre-miRNA oligonucleotides were cloned into vector pcDNA6.2-GW-miR as recommended by the manufacturer's protocol, resulting in four 3D-specific miRNA expression plasmids (p3D657-miR, p3D715-miR, p3D983-miR, and p3D1311-miR) and a negative control miRNA expression plasmid (pNC-miR). The recombinant plasmids were confirmed as positive by DNA sequencing. Mutant sequences in these inserted oligonucleotides were excluded from this experiment. The predicted structures of the vector-delivered pre-miRNAs incorporated into the murine miR-155 backbone are shown in Figure 2. To construct reporter plasmids, the RT-PCR products were recovered from an agarose gel and digested with XbaI/KpnI, then cloned into the XbaI/KpnI-digested pcDNA3.1-CT-GFP vector, designated as p3D-GFP. The reporter plasmid was confirmed as positive by restriction enzyme digestion, PCR, and sequence analysis. Sequence analysis showed that the amplified 3D cDNA was 100% identical to FMDV O/CHA/99 isolates (GenBank accession number AF506822) . The plasmids used for transfection were purified using the QIAGEN plasmid Midi Kit (Qiagen, Germany). After p3D-GFP transfection (24-48 h), typical fluorescence-positive cells were observed by fluorescence microscopy (data not shown), showing that the transient expression systems transfected with p3D-GFP were suitable as an indicator to test the efficiency of inhibition by miRNAs.
Silencing effects of reporter gene expression by miRNAs
When BHK-21 cells were co-transfected with miRNA expression and reporter (p3D-GFP) plasmids, four miRNA expression plasmids were able to significantly silence the expression of the reporter plasmid, resulting in a remarkable reduction in GFP signal relative to the control samples that were co-transfected with miRNA expression plasmids and blank plasmid, pcDNA3.1-CT-GFP. The negative control construct (pNC-miR) showed no significant reduction of GFP expression (Figure 3). Compared to the p3D675-miR and p3D1311-miR plasmids, the plasmids, p3D715-miR and p3D983-miR, showed more reduction of GFP expression in BHK-21 cells.
Effective inhibition of FMDV replication by miRNAs
BHK-21 cells were transfected with miRNA expression plasmids, and then infected with 100 μl TCID50 of FMDV O/CHA/99. Transfected BHK-21 cells are fibroblastic, grow in a monolayer, and have a well-defined tendency towards parallel orientation. Viral infection causes a marked cytopathic effect (CPE) ending in total cellular detachment, isolation, and destruction, which can be observed by microscopy. Microscopic examination revealed that the CPE on infected cells was delayed when the BHK-21 cells were transfected with miRNA-expressing plasmids, whereas cells transfected with the negative control plasmid (pNC-miR) showed an extensive CPE within 24 h after infection. Viral titers decreased from 105TCID50 in pNC-miR transfected cells to 104.2, 102.4, 103.3 and 104.0TCID50 in p3D675-miR, p3D715-miR, p3D983-miR and p3D1311-miR transfected cells 24 h after infection, respectively (Figure 4). In addition to the examination of the yield of progeny virus, we also tested the silencing effect of FMDV replication on the viral RNA load. Melt-curve analysis confirmed specific amplification of real-time RT-PCR products. Using cDNA templates, the efficiency of the PCR reactions for GAPDH and 3D were shown to be similar, permitting the relative abundance of the integrated mRNA to be estimated. Real-time RT-PCR products were analyzed on 3% agarose gel. The cDNA fragments with the expected size for GAPDH and 3D were amplified and no primer dimers were detected. To confirm their specificity, the real-time RT-PCR products were sequenced and showed 100% identity with the reference gene. Real-time RT-PCR analyses showed that the expression of FMDV 3D was inhibited 46.3, 82.1, 68.1 and 41.5% by p3D675-miR, p3D715-miR, p3D983-miR and p3D1311-miR transfection 24 h after infection, respectively, compared with the levels of viral RNA in pNC-miR transfected cells (Figure 5). At 48 h after infection, four miRNA expression plasmids still had marked inhibitory effects on the replication of FMDV, although the effect of inhibition was not as good as 24 h after infection. Effective inhibition was greater in cells transfected with p3D715-miR and p3D983-miR (Figures 4 and 5).
RNAi triggered by small RNA molecules, including siRNAs and miRNAs, offers a new approach for controlling viral infections [26–28]. siRNAs, derived by processing long double-stranded RNAs, are often of exogenous origin, degrade mRNAs bearing full complementary sequences, and are currently being extensively evaluated as potential antiviral tools. In contrast, miRNAs, which are endogenously encoded and derived by processing of long hairpin RNA precursors, can either cleave mRNAs bearing full complementary sequences or inhibit translation of mRNAs bearing partial complementary sequences [29, 30]. It is believed that miRNAs are essential regulators of various processes, such as cellular differentiation, proliferation, development, apoptosis and pathogen-host interactions [30–32]. The antiviral potential of siRNAs has been comprehensively discussed in numerous reviews [26, 28, 33, 34]. Thus far, there is no report available for FMDV inhibition by vector-delivered miRNA, though miRNA is believed to have more potential than siRNA/shRNA [35, 36]. In the present study, we systematically evaluated the effects of miRNA-based RNAi on FMDV expression and replication in BHK-21 cells. Our results showed that miRNA-based RNAi could inhibit FMDV 3D protein expression and FMDV replication in vitro. This study is the first report to apply vector-delivered miRNA to inhibit FMDV replication.
Several researchers have shown that siRNA/shRNA targeting the 3D gene could efficiently inhibit FMDV replication. Moreover, according to their reports, viral inhibition triggered by siRNA/shRNA and targeting the 3D gene seems more efficient compared to other genes within the same genome [11, 14, 37]. Here we demonstrated that plasmid-based miRNAs designed against the FMDV 3D gene could strongly inhibit virus replication in the infected BHK-21 cells. Together with the results from previous studies, we are convinced that the 3D gene could be a good target for intervention in FMDV replication. It remains to be tested whether genes other than 3D could be miRNA targets. It has been shown that siRNAs against VP1, 2B, 3C and 5'UTR were highly effective inhibiting viral replication [11, 13, 15, 37]. In our experiment, only four sequences of 3D were tested; therefore, we cannot exclude the significance of other genes of FMDV as effective targets for inhibition.
By incorporating sequences encoding miRNAs specific to the 3D gene of FMDV into a murine miR-155 pre-miRNA backbone under control of Pol II promoter (CMV), we were able to intracellularly express miRNAs in cells transfected with miRNA plasmids coding pre-miRNAs. Theoretically, this type of vector provides unique benefits in designing antiviral therapies [17, 18, 36]. This strategy allows multiple miRNAs to be expressed coordinately from a single precursor RNA and processed into individual miRNAs [17, 38]. It remains to be investigated whether combining different miRNA-3D targets can improve the inhibitory effect beyond what we observed with miRNA-3D alone. To facilitate effective miRNA selection, the reporter vector p3D-EGFP was used to estimate gene silencing effects in transfected BHK-21 cells. Fluorescence microscopy showed dissimilar, but significant, decreases in GFP-positive cell numbers by co-transfection with all four 3D-specific miRNA expression vectors, but not by the control miRNA expression vector, indicating the high confidence of the web-based tool for miRNA prediction and the specificity of the gene silencing effects of the vector-delivered miRNAs. The efficiency of gene silencing varied between miRNAs targeted to different regions of the 3D gene. At present, there is no information available about the mechanisms that determine the gene-silencing efficiency of a given miRNA. Further work needs to be completed to test the relationship between miRNA silencing efficiency and targeted genes.
Our results indicate that vector-delivered miRNAs targeting the 3D gene effectively inhibits FMDV replication in vitro. This finding provides evidence that miRNAs could be used as a potential tool against FMDV infection. Further studies are required to determine whether the technology offers protection against FMDV infection in vivo. However, this work represents a significant advancement, describing another approach to trigger anti-FMDV pathways through actions of miRNAs.
Alexandersen S, Mowat GN: Foot-and-mouth disease: host range and pathogenesis. Curr Top Microbiol Immunol 2005, 288: 9-42. 10.1007/3-540-27109-0_2
Thomson GR, Vosloo W, Bastos ADS: Foot and mouth disease in wildlife. Virus Res 2003, 91: 145-161. 10.1016/S0168-1702(02)00263-0
Grubman MJ, Baxt B: Foot-and-mouth disease. Clin Microbiol Rev 2004, 17: 465-493. 10.1128/CMR.17.2.465-493.2004
Belsham GJ: Translation and replication of FMDV RNA. Curr Top Microbiol Immunol 2005, 288: 43-70. 10.1007/3-540-27109-0_3
Du J, Chang H, Cong G, Shao J, Lin T, Shang Y, Liu Z, Liu X, Cai X, Xie Q: Complete nucleotide sequence of a Chinese serotype Asia1 vaccine strain of foot-and-mouth disease virus. Virus Genes 2007,35(3):635-642. 10.1007/s11262-007-0126-8
Ferrer-Orta C, Agudo R, Domingo E, Verdaguer N: Structural insights into replication initiation and elongation processes by the FMDV RNA-dependent RNA polymerase. Curr Opin Struct Biol 2009,19(6):752-758. 10.1016/j.sbi.2009.10.016
Arias A, Arnold JJ, Sierra M, Smidansky ED, Domingo E, Cameron CE: Determinants of RNA-dependent RNA polymerase (in)fidelity revealed by kinetic analysis of the polymerase encoded by a foot-and-mouth disease virus mutant with reduced sensitivity to ribavirin. J Virol 2008, 82: 12346-12355. 10.1128/JVI.01297-08
Fire A, Xu S, Montgomery MK, Kostas SA, Driver SE, Mello CC: Potent and specific genetic interference by double-stranded RNA in C . elegans. Nature 1998, 391: 806-811. 10.1038/35888
Elbashir S M, Harborth J, Lendeckel W, Yalcin A, Weber K, Tuschl T: Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 2001, 411: 494-498. 10.1038/35078107
Cullen BR: Derivation and function of small interfering RNAs and microRNAs. Virus Res 2004, 102: 3-9. 10.1016/j.virusres.2004.01.009
Chen W, Liu M, Jiao Y, Yan W, Wei X, Chen J, Fei L, Liu Y, Zuo X, Yang F, Lu Y, Zheng Z: Adenovirus-mediated RNA interference against foot-and mouth disease virus infection both in vitro and in vivo. J Virol 2006,80(7):3559-3566. 10.1128/JVI.80.7.3559-3566.2006
Chen W, Yan W, Du Q, Fei L, Liu M, Ni Z, Sheng Z, Zheng Z: RNA interference targeting VP1 inhibits foot-and-mouth disease virus replication in BHK-21 cells and suckling mice. J Virol 2004,78(13):6900-6907. 10.1128/JVI.78.13.6900-6907.2004
de los Santos T, Wu Q, Botton S, Grubman MJ: Short hairpin RNA targeted to the highly conserved 2B nonstructural protein coding region inhibits replication of multiple serotypes of foot-and-mouth disease virus. Virology 2005,335(2):222-231. 10.1016/j.virol.2005.03.001
Kahana R, Kuznetzova L, Rogel A, Shemesh M, Hai D, Yadin H, Stram Y: Inhibition of foot-and-mouth disease virus replication by small interfering RNA. J Gen Virol 2004, 85: 3213-3217. 10.1099/vir.0.80133-0
Kim SM, Lee KN, Park JY, Ko YJ, Joo YS, Kim HS, Park JH: Therapeutic application of RNA interference against foot-and-mouth disease virus in vitro and in vivo. Antiviral Res 2008, 80: 178-184. 10.1016/j.antiviral.2008.06.001
Wang P, Ren Y, Guo Z, Chen C: Inhibition of foot-and-mouth disease virus replication in vitro and in vivo by small interfering RNA. Virol J 2008, 5: 86. 10.1186/1743-422X-5-86
Chung KH, Hart CC, Al-Bassam S, Avery A, Taylor J, Patel PD, Vojtek AB, Turner DL: Polycistronic RNA polymerase II expression vectors for RNA interference based on BIC/miR-155. Nucleic Acids Res 2006, 34: e53. 10.1093/nar/gkl143
Stegmeier F, Hu G, Rickles RJ, Hannon GJ, Elledge SJ: A lentiviral microRNA-based system for single-copy polymerase II-regulated RNA interference in mammalian cells. Proc Natl Acad Sci USA 2005, 102: 13212-13217. 10.1073/pnas.0506306102
Boden D, Pusch O, Lee F, Tucker L, Ramratnam B: Human immunodeficiency virus type 1 escape from RNA interference. J Virol 2003, 77: 11531-11535. 10.1128/JVI.77.21.11531-11535.2003
Qu J, Ye J, Fang R: Artificial microRNA-mediated virus resistance in plants. J Virol 2007, 81: 6690-6699. 10.1128/JVI.02457-06
McBride JL, Boudreau RL, Harper SQ, Staber PD, Monteys AM, Martins I, Gilmore BL, Burstein H, Peluso RW, Polisky B, Carter BJ, Davidson BL: Artificial miRNAs mitigate shRNA-mediated toxicity in the brain: implications for the therapeutic development of RNAi. Proc Natl Acad Sci USA 2008, 105: 5868-5873. 10.1073/pnas.0801775105
Zhang X, Liu Z, Zhao Q, Chang H, Xie Q: Sequencing and analysis for the full-length genome RNA of foot-and-mouth disease virus China/99. Sci China C Life Sci 2004,47(1):74-81. 10.1360/02yc0169
Reed LJ, Muench HA: A Simple method of estimating fifty percent end points. Am J Hyg 1938, 27: 493-497.
Livak KJ, Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2--ΔΔCtmethod. Methods 2001, 25: 402-408. 10.1006/meth.2001.1262
Du J, Chang H, Gao S, Xue S, Cong G, Shao J, Lin T, Liu Z, Liu X, Cai X: Molecular characterization and expression analysis of porcine integrins αvβ3, αvβ6 and αvβ8 that are potentially involved in FMDV infection. Mol Cell Probes 2010, 24: 256-265. 10.1016/j.mcp.2010.04.005
Lim TW, Yuan J, Liu Z, Qiu D, Sall A, Yang D: Nucleic-acid based antiviral agents against positive single-stranded RNA viruses. Curr Opin Mol Ther 2006,8(2):104-107.
Voinnet O: Induction and suppression of RNA silencing: insights from viral infections. Nat Rev Genet 2005,6(3):206-220. 10.1038/nrg1555
Spurgers KB, Sharkey MC, Warfield KL, Bavari S: Oligonucleotide antiviral therapeutics: Antisense and RNA interference for highly pathogenic RNA viruses. Antiviral Res 2008, 78: 26-36. 10.1016/j.antiviral.2007.12.008
Zeng Y, Yi R, Cullen BR: MicroRNAs and small interfering RNAs can inhibit mRNA expression by similar mechanisms. Proc Natl Acad Sci USA 2003, 100: 9779-9784. 10.1073/pnas.1630797100
Bartel D P: MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004, 116: 281-297. 10.1016/S0092-8674(04)00045-5
Ying SY, Chang DC, Miller JD, Lin SL: The microRNA: overview of the RNA gene that modulates gene functions. Methods Mol Biol 2006, 342: 1-18.
Miska EA: How microRNAs control cell division, differentiation and death. Curr Opin Genet Dev 2005, 15: 563-568. 10.1016/j.gde.2005.08.005
Tan FL, Yin JQ: RNAi, a new therapeutic strategy against viral infection. Cell Res 2004, 14: 460-466. 10.1038/sj.cr.7290248
Pushparaj PN, Melendez AJ: Short interfering RNA (siRNA) as a novel therapeutic. Clin Exp Pharmacol Physiol 2006, 33: 504-510. 10.1111/j.1440-1681.2006.04399.x
Gao YF, Yu L, Wei W, Li JB, Luo QL, Shen JL: Inhibition of hepatitis B virus gene expression and replication by artificial microRNA. World J Gastroenterol 2008,14(29):4684-4689. 10.3748/wjg.14.4684
Israsenaa N, Supavonwongb P, Ratanasetyuthb N, Khawplodc P, Hemachudha T: Inhibition of rabies virus replication by multiple artificial microRNAs. Antiviral Res 2009, 84: 76-83. 10.1016/j.antiviral.2009.07.012
Lecellier CH, Dunoyer P, Arar K, Lehmann-Che J, Eyquem S, Himber C, Saib A, Voinnet O: A cellular microRNA mediates antiviral defense in human cells. Science 2005, 308: 557-560. 10.1126/science.1108784
Xia XG, Zhou H, Xu Z: Multiple shRNAs expressed by an inducible pol II promoter can knock down the expression of multiple target genes. Biotechniques 2006, 41: 64-68. 10.2144/000112198
This work was supported by National Major Special Project on New Varieties Cultivation for Transgenic Organisms (No. 2009ZX08007-008B, No. 2009ZX08006-002B, and No. 2009ZX08008-010B); National Natural Science Foundation of China (No. 30800833); and Nature Science Foundation of Gansu Province, China (No.1010RJZA003).
The authors declare that they have no competing interests.
JD participated in planning of the study and carried out majority of the experiments and drafted the manuscript. HC and XC conceived the study and helped to draft the manuscript. SG, JL and GZ performed the construction and purification of all plasmids. GC, JS and TL participated in cell and virus cultures. All authors read and approved the final manuscript.